642 related articles for article (PubMed ID: 32703039)
41. Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons.
Makabe K; Okada H; Tachibana N; Ishikura H; Ito N; Tanaka M; Chijimatsu R; Terashima A; Yano F; Asaka M; Yanagihara D; Taketomi S; Matsumoto T; Tanaka S; Omata Y; Saito T
Arthritis Res Ther; 2024 Jun; 26(1):121. PubMed ID: 38879555
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of baricitinib in the treatment of rheumatoid arthritis.
Richez C; Truchetet ME; Kostine M; Schaeverbeke T; Bannwarth B
Expert Opin Pharmacother; 2017 Sep; 18(13):1399-1407. PubMed ID: 28737053
[TBL] [Abstract][Full Text] [Related]
43. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Taylor PC
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
[TBL] [Abstract][Full Text] [Related]
44. Baricitinib: From Rheumatoid Arthritis to COVID-19.
Assadiasl S; Fatahi Y; Mosharmovahed B; Mohebbi B; Nicknam MH
J Clin Pharmacol; 2021 Oct; 61(10):1274-1285. PubMed ID: 33870531
[TBL] [Abstract][Full Text] [Related]
45. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
Wollenberg A; Nakahara T; Maari C; Peris K; Lio P; Augustin M; Silverberg JI; Rueda MJ; DeLozier AM; Pierce E; Yang FE; Sun L; Ball S; Tauber M; Paul C
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1543-1552. PubMed ID: 33834521
[TBL] [Abstract][Full Text] [Related]
46. Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.
Kołkowski K; Trzeciak M; Sokołowska-Wojdyło M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948183
[TBL] [Abstract][Full Text] [Related]
47. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
48. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
He Q; Xie X; Chen Q; Li W; Song Z; Wang X; Ma X; Zeng J; Guo J
Front Immunol; 2024; 15():1342810. PubMed ID: 38464512
[TBL] [Abstract][Full Text] [Related]
49. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
Reich K; DeLozier AM; Nunes FP; Thyssen JP; Eichenfield LF; Wollenberg A; Ross Terres JA; Watts SD; Chen YF; Simpson EL; Silverberg JI
J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
[TBL] [Abstract][Full Text] [Related]
50. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Mogul A; Corsi K; McAuliffe L
Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
[No Abstract] [Full Text] [Related]
51. Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib.
Xia D; Xiao Y; Li M; Li W
Dermatol Ther; 2022 Sep; 35(9):e15724. PubMed ID: 35855568
[No Abstract] [Full Text] [Related]
52. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
53. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
[TBL] [Abstract][Full Text] [Related]
54. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
[TBL] [Abstract][Full Text] [Related]
55. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
[TBL] [Abstract][Full Text] [Related]
56. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
Bieber T; Thyssen JP; Reich K; Simpson EL; Katoh N; Torrelo A; De Bruin-Weller M; Thaci D; Bissonnette R; Gooderham M; Weisman J; Nunes F; Brinker D; Issa M; Holzwarth K; Gamalo M; Riedl E; Janes J
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):476-485. PubMed ID: 32926462
[TBL] [Abstract][Full Text] [Related]
57. Acute spondyloarthritis developing during successful treatment with dupilumab for severe atopic dermatitis.
Raimondo A; Guglielmi G; Marino C; Ligrone L; Lembo S
Clin Exp Dermatol; 2022 Mar; 47(3):592-593. PubMed ID: 34655234
[No Abstract] [Full Text] [Related]
58. Real-world experience of baricitinib in atopic dermatitis: including add-on therapy for patients using dupilumab.
Lim JH; Kwon SH; Lew BL
Int J Dermatol; 2024 Feb; 63(2):196-200. PubMed ID: 38058206
[TBL] [Abstract][Full Text] [Related]
59. Abrocitinib for the treatment of atopic dermatitis.
Crowley EL; Nezamololama N; Papp K; Gooderham MJ
Expert Rev Clin Immunol; 2020 Oct; 16(10):955-962. PubMed ID: 32969750
[TBL] [Abstract][Full Text] [Related]
60. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
